NICE recommends Tecfidera as a treatment for Multiple Sclerosis-Biogen IDEC

NICE has now recommended that Tecfidera (dimethyl fumarate) from Biogen IDEC, be offered to adults with relapsing remitting Multiple Sclerosis whose disease is not highly active or rapidly evolving. The cost of Tecfidera at �16 000 which was the original stumbling block in securing NICE support for the drug but a patient access scheme and a discount has resulted in a recommendation keeping Tecfidera up with its competitors, Gilenya and Aubagio who have NICE recommendations in the UK.